Microbot Medical Inc.

Microbot Medical Inc. announced it has won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY Endovascular Robotic System. This award recognizes companies with outstanding technological and commercial progress through groundbreaking technologies. The LIBERTY system, which is FDA-cleared and remotely operated, is being adopted by leading academic centers across several states, further validating its impact on robotic-assisted endovascular care.

Microbot Medical Inc. announced that a globally recognized academic center in Pennsylvania has adopted its LIBERTY® Endovascular Robotic System, marking the first adoption in the state. This expands the company's presence to seven states across the Eastern U.S. The company also plans to expand its sales territory to the West Coast and into U.S. federal healthcare systems.

Microbot Medical Inc. announced a vendor agreement with Lovell Government Services to expand access for its LIBERTY® Endovascular Robotic System. This partnership will enable the sale of the LIBERTY® System to over 2,000 U.S. government facilities, including those under the Veterans Health Administration, Military Health System, and Indian Health Service. Lovell Government Services will serve as the Company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, streamlining procurement and helping government agencies meet SDVOSB goals.

Microbot Medical Inc. has entered into an agreement with Lovell Government Services to expand the reach of its LIBERTY® Endovascular Robotic System to federal healthcare systems, including the VHA, MHS, and IHS. Lovell will act as the Company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, aiming to streamline the sales process and help government agencies meet procurement goals. The LIBERTY System is expected to be added to Lovell's Federal Supply Schedule (FSS) contract in Q3 2026 and will also be available through other federal procurement platforms. This partnership is anticipated to increase awareness and adoption of Microbot's technology among veterans and active-duty service members.

Microbot Medical Inc. announced it has secured its first Midwest-based account, a major healthcare system in Michigan, for its LIBERTY Endovascular Robotic System. This expansion into Michigan and the greater Midwest follows a recent customer acquisition in North Carolina, demonstrating the company's continued execution of its full market release strategy in the U.S. The company believes this reflects growing demand for advanced robotic solutions in peripheral endovascular procedures, a market estimated at 2.5 million procedures annually.

Microbot Medical announced that a major Michigan healthcare system has adopted its LIBERTY Endovascular Robotic System, marking its first presence in Michigan and the greater Midwest U.S. This follows a recent expansion into North Carolina, indicating growing interest and demand for advanced robotic solutions in peripheral endovascular procedures. The company highlights the U.S. market opportunity of approximately 2.5 million annual procedures and the LIBERTY system's unique FDA clearance and recent Israeli regulatory approval.

Microbot Medical Inc. announced it has secured its first North Carolina-based customer for the LIBERTY Endovascular Robotic System. This new account, a multi-hospital network, signifies a broadening geographic penetration for the system across the Southeast, Mid-Atlantic, and Northeast U.S. The company views this as continued execution of its commercial strategy and anticipates further expansion into major metropolitan markets and academic institutions.

Microbot Medical Inc. announced that Israel has granted marketing clearance for its LIBERTY Endovascular Robotic System, making it the second jurisdiction and the first outside the U.S. to do so. This regulatory approval from the Israeli Ministry of Health's AMAR Division allows the company to market and commercialize the system in Israel and obtain a Free Sale Certificate to support expansion into other international markets. The company is also working towards CE Mark certification by the end of 2026 for entry into the EU market, following a successful launch in the U.S. where it has been adopted by multiple hospitals.

Microbot Medical Inc. announced it will host an analysts and investors conference call on Monday, May 18th, at 3:00pm ET. The call aims to review the recent progress of the LIBERTY Endovascular Robotic System's Full Market Release and to correct misleading statements and misrepresentations made by a recent unaffiliated third-party article. CEO Harel Gadot will be joined by LIBERTY users Dr. Charles Briggs and Dr. Zachary L. Bercu, with Dr. Briggs specifically addressing inaccuracies attributed to him in the article.

Microbot Medical Inc. announced it will host an analysts and investors conference call on May 18th to address and correct misleading statements and misrepresentations made in a recent unaffiliated third-party article. The company aims to ensure the investing public is fully informed about its LIBERTY Endovascular Robotic System. A Wall Street firm has already published a research report refuting the article's claims, and a vascular surgeon will also dispute assertions attributed to him during the call. The conference will also cover the recent progress of the LIBERTY System's Full Market Release.